DE4032730A1 - Enzymatic metabolic material for treating gastrointestinal disorders - produced from intestinal lacto- and bifido-bacteria, which are used to ferment a vegetable mass - Google Patents
Enzymatic metabolic material for treating gastrointestinal disorders - produced from intestinal lacto- and bifido-bacteria, which are used to ferment a vegetable massInfo
- Publication number
- DE4032730A1 DE4032730A1 DE4032730A DE4032730A DE4032730A1 DE 4032730 A1 DE4032730 A1 DE 4032730A1 DE 4032730 A DE4032730 A DE 4032730A DE 4032730 A DE4032730 A DE 4032730A DE 4032730 A1 DE4032730 A1 DE 4032730A1
- Authority
- DE
- Germany
- Prior art keywords
- vegetable mass
- vitamins
- vegetable
- intestinal
- prod
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000013311 vegetables Nutrition 0.000 title claims abstract description 17
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 13
- 230000002255 enzymatic effect Effects 0.000 title claims abstract description 11
- 230000002503 metabolic effect Effects 0.000 title claims abstract description 9
- 241000186000 Bifidobacterium Species 0.000 title claims abstract description 5
- 239000000463 material Substances 0.000 title description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 title 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 9
- 235000013343 vitamin Nutrition 0.000 claims abstract description 9
- 239000011782 vitamin Substances 0.000 claims abstract description 9
- 229940088594 vitamin Drugs 0.000 claims abstract description 9
- 229930003231 vitamin Natural products 0.000 claims abstract description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 6
- 235000012907 honey Nutrition 0.000 claims abstract description 6
- 235000021537 Beetroot Nutrition 0.000 claims abstract description 5
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 4
- 238000000855 fermentation Methods 0.000 claims abstract description 4
- 230000004151 fermentation Effects 0.000 claims abstract description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 4
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 4
- 239000004310 lactic acid Substances 0.000 claims abstract description 4
- 239000011707 mineral Substances 0.000 claims abstract description 4
- 244000000626 Daucus carota Species 0.000 claims abstract description 3
- 235000002767 Daucus carota Nutrition 0.000 claims abstract description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 240000001949 Taraxacum officinale Species 0.000 claims abstract description 3
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 3
- 244000274883 Urtica dioica Species 0.000 claims abstract description 3
- 235000009108 Urtica dioica Nutrition 0.000 claims abstract description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 3
- 239000005862 Whey Substances 0.000 claims abstract description 3
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 3
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 3
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 3
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 3
- 239000012141 concentrate Substances 0.000 claims abstract description 3
- 235000009508 confectionery Nutrition 0.000 claims abstract description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 3
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 3
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 3
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 3
- 235000021108 sauerkraut Nutrition 0.000 claims abstract description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 2
- 239000001301 oxygen Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 244000286916 Ratibida columnifera Species 0.000 claims description 2
- 235000009413 Ratibida columnifera Nutrition 0.000 claims description 2
- 235000001466 Ribes nigrum Nutrition 0.000 claims description 2
- 241001312569 Ribes nigrum Species 0.000 claims description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 2
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 2
- 235000021014 blueberries Nutrition 0.000 claims description 2
- 235000014134 echinacea Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 230000003068 static effect Effects 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 5
- 230000007246 mechanism Effects 0.000 abstract description 5
- 206010010774 Constipation Diseases 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 239000000654 additive Substances 0.000 abstract description 3
- 206010016766 flatulence Diseases 0.000 abstract description 3
- QPRMGHKASRLPJP-UHFFFAOYSA-N 12-(5-hydroxy-6-methylpiperidin-2-yl)dodecan-2-one Chemical compound CC1NC(CCCCCCCCCCC(C)=O)CCC1O QPRMGHKASRLPJP-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- OGPQOSAKRHKIHW-UHFFFAOYSA-N Cassin Natural products CC(CCCCCCCCCC1CCC(O)C(C)N1)C(=O)C OGPQOSAKRHKIHW-UHFFFAOYSA-N 0.000 abstract 1
- 244000078534 Vaccinium myrtillus Species 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 238000001784 detoxification Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000007102 metabolic function Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 2
- 241001112696 Clostridia Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000037189 immune system physiology Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000004882 Intestinal Polyposis Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000008993 bowel inflammation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000019993 champagne Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/56—Lactic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Die Erfindung betrifft ein enzymatisches Stoffwechsel produkt aus darmresidenten Lacto- und Bifido-Bakterien zur Gewinnung hochkonzentrierter L-(+)-Milchsäure und Fermentation einer vegetabilen Masse zur Endversorgung der Zellen und deren O2-Utilisation.The invention relates to an enzymatic metabolism product from intestinal lacto and bifido bacteria for the production of highly concentrated L - (+) - lactic acid and fermentation of a vegetable mass for the final supply of the cells and their O 2 utilization.
Sie betrifft ferner ein Verfahren zur Herstellung die ses Stoffwechselprodukts.It also relates to a method for producing the metabolic product.
Die Forderung nach aktiven biologischen Systemen als reparative Mechanismen für den durch toxische Belastung, Immuninsuffizienz, O2-Utilisations- und Permeabilitäts schäden der Zellmembran, Entgiftungs-, Assimilations- und Stoffwechselstörungen, Candidabefall, Mykosen, Al lergosen, Enzym- und Regelsystemblockaden schwer an geschlagenen menschlichen Organismus ist zwingend. Die Ursachen dieser Schäden des menschlichen Organismus sind in der Regel in einem seit Jahren gestörten oder bereits folgenschwer pathogen veränderten Darmmilieu zu suchen. Die Gründe hierfür sind durch wissenschaft liche Erkenntnisse gesichert. Neben den klassischen Auslösungsmechanismen, jahrelanger Ernährungsabusus, sind es gerade die iatrogenen Maßnahmen mit Antibioti ka, Kortison, kortikoidhaltigen Arzneimitteln, Sulfona miden, Laxandien, Ovulationshemmer, Immunsuppressiva und Medikamentenabusus, die die säurebildende mensch liche Darmflora teilweise oder vollständig eliminieren.The demand for active biological systems as reparative mechanisms for those affected by toxic stress, immune insufficiency, O 2 utilization and permeability damage to the cell membrane, detoxification, assimilation and metabolism disorders, candidiasis, mycoses, allergies, enzyme and control system blockages human organism is imperative. The causes of this damage to the human organism can usually be found in an intestinal environment that has been disturbed for years or has already had a pathogenic change. The reasons for this are backed up by scientific knowledge. In addition to the classic trigger mechanisms, years of nutritional abuse, it is precisely the iatrogenic measures with antibiotics, cortisone, corticoid drugs, sulfonamides, laxatives, ovulation inhibitors, immunosuppressants and drug abuse that partially or completely eliminate the acid-producing human intestinal flora.
Die hieraus resultierende Dickdarm-pH-Verschiebung in Richtung pH 7, also neutral, löst eine invasive Stoff wechseltätigkeit der mit eigenen Enzymen ausgestatte ten, als obligat pathogen geltenden Keime wie beispiels weise E. coli, Enterobakt. und Clostridien (Fäulnis- und Ammoniakgasbildner) aus, deren Wachstumsoptimum bei pH 6,0 und darüber liegt. Cholsäure wird umgespalten und Ammoniakgase, beides im hohen Maße cancerogene Toxine, gebildet. Bei einem pH-Wert von 6,5 erfolgt keine quan titative Ausleitung mehr. Endogene und exogene Toxine diffundieren durch die Darmwand und belasten Leber, Bauchspeicheldrüse, Regelsysteme und Zellen. Die Auto toxikation läuft. Das Intestinum wird unphysiologisch. Entgiftungs-, Resorptions- und Stoffwechselfunktionen werden nicht mehr ausreichend erfüllt und das humorale und zelluläre Immunsystem wird insuffizient.The resulting colon pH shift in Towards pH 7, i.e. neutral, triggers an invasive substance change activity of the equipped with their own enzymes germs considered obligatory pathogens such as wise E. coli, enterobact. and clostridia (putrefactive and Ammonia gas generator), whose growth optimum at pH 6.0 and above. Cholic acid is split and Ammonia gases, both highly carcinogenic toxins, educated. At a pH of 6.5 there is no quan titative diversion more. Endogenous and exogenous toxins diffuse through the intestinal wall and strain the liver, Pancreas, regulatory systems and cells. The car toxicity is running. The intestine becomes non-physiological. Detoxification, absorption and metabolism functions are no longer sufficiently fulfilled and the humoral and cellular immune system becomes insufficient.
Die Erfindung stellt sich daher die Aufgabe, ein en zymatisches Stoffwechselprodukt der genannten Art zu entwickeln, das sicherstellt, daß Entgiftungs-, Resorp tions- und Stoffwechselfunktionen des Darms wieder in einem ausreichenden Maße erfüllt werden und die immuno logischen Abläufe sowie die Selbstheilungskräfte akti viert, so daß Obstipationen, colon irritabile, Völlege fühl, Gasbildung, Flatulenz und Müdigkeit sowie die durch diese Symptome erfolgende Auslösung stoffwechsel abhängiger Zivilisationskrankheiten mit ihren gefürch teten Komplikationen vermieden werden.The invention is therefore an object zymatic metabolite of the type mentioned develop that ensures that detoxification, resorp tion and metabolic functions of the intestine again are met sufficiently and the immuno logical processes and the self-healing powers acti fourth, so constipations, colon irritabile, Völlege feeling, gas formation, flatulence and fatigue as well as the metabolism triggered by these symptoms dependent civilization diseases with their fear complications can be avoided.
Diese Aufgabe wird dadurch gelöst, daß die vegetabile
Masse sich zusammensetzt aus wenigstens einigen der
folgenden Vegetabil- und Vitalstoffe:
Mineraltiefbrunnen, Süßmolke-Konzentrat, Blütenpollen,
Wildblütenhonig, Waldhonig, Sauerkraut, Brennessel, Lö
wenzahn und Wurzeln/Blätter/Blüten des schmalblättrigen
Sonnenhuts, rote Bete, Heidelbeeren, Cassis und Karot
ten, und daß die Zutaten bestehen aus: Kalium, Calcium,
Calcium Orthophosphat, Eisen, Vitamin dl-E-acetat, B1,
B2, B6, Niacin und Ascorbinsäure, und daß der Anteil
der Vitamine etwa dem halben Deckungsbedarf pro Tag,
die Gesamtmilchsäure 4,2%/100 ml und der ph-Wert 2,9-3,4
betragen.This object is achieved in that the vegetable mass is composed of at least some of the following vegetable and vital substances:
Mineral deep well, sweet whey concentrate, pollen, wildflower honey, forest honey, sauerkraut, nettle, dandelion and roots / leaves / flowers of the narrow-leaved coneflower, beetroot, blueberries, cassis and carrot, and that the ingredients consist of: potassium, calcium, calcium Orthophosphate, iron, vitamin dl-E-acetate, B1, B2, B6, niacin and ascorbic acid, and that the proportion of vitamins is about half the need for coverage per day, total lactic acid 4.2% / 100 ml and pH 2, 9-3.4.
Zur Herstellung dieses enzymatischen Stoffwechselpro dukts dient erfindungsgemäß ein Verfahren, das sich da durch kennzeichnet, daß die vegetabile Masse und die Zu taten in einer Desintegrationseinrichtung mit Hilfe ro tierender Schlagelemente mikrofein zerkleinert, vermischt und aktiviert werden.To produce this enzymatic metabolism pro According to the invention, a product serves as a product by indicates that the vegetable mass and the zu did in a disintegration facility using ro animal impact elements microfine crushed, mixed and be activated.
Durch das erfindungsgemäße enzymatische Stoffwechsel produkt wird die natürliche Darmflora wieder hergestellt, indem der in den pH-Wertbereich von über 6,0 entgleiste pH-Wert auf Werte unter 6,0 gesenkt wird, die zur Folge haben, daß die Gallensäure dekonjugierenden Clostridien keime zerstört werden und enzymatische Verstoffwechse lungsprozesse ammoniakgasbildender Fäulnisfloren nicht mehr stattfinden. Die kontinuierliche Ansäuerung stoppt die Toxinproduktion, die vermehrten pathologischen Kei me und die Toxine werden über die Darmlymphe ausgeleitet, wodurch die Leber entlastet wird. Through the enzymatic metabolism according to the invention the natural intestinal flora is restored, by derailing in the pH range of over 6.0 pH is lowered to values below 6.0, which results have that bile acid deconjugating clostridia germs are destroyed and enzymatic metabolism processes of ammonia gas-forming putrefactive flora more take place. The continuous acidification stops the production of toxins, the increased pathological germ me and the toxins are removed via the intestinal lymph, which relieves the liver.
Entgiftungs-, Stoffwechsel- und Resorptionsmechanismen werden reanimiert. Die säurebildenden Keime, Immunsy steme und die Selbstheilungskräfte kommen in die Rege nerationsphase.Detoxification, metabolism and absorption mechanisms are reanimated. The acid-producing germs, Immunsy steme and the self-healing powers come into play generation phase.
Das erfindungsgemäße enzymatische Stoffwechselprodukt bewirkt die Endversorgung der Zellen durch fermentier te Biokatalysatoren in Form eines Wirkstoffkomplexes von Enzymen, Aminosäuren, mikrofein dispergierten Heil pflanzen, Mineralstoffen und Vitaminen. Betazyane aus den Farbkörpern der roten Bete und anderen roten Früch ten unterstützen die O2-Utilisation der Zellen. Das Stoffwechselprodukt ist somit ein Diätetikum, das die Herstellung eines adäquaten, wachstumsoptimalen Milieus des menschlichen Dickdarms, also eines Milieus unter pH 6,0 bewirkt bei gleichzeitiger Substitution lebens fähiger Mischkulturen, bestehend aus apathogenen darm gleichen Lactobazillen und Bifidusstämmen. Die Anwen dung dieses erfindungsgemäßen Diätetikums bewirkt eine Therapie, zu der die Reanimierung der säurebildenden Darmflora bzw. die Neuansiedlung dieser Floren gehört und die parallel zur Therapie der stoffwechselabhän gigen Hauterkrankung, also einer der zahlreichen be kannten Zivilisationskrankheiten, wie Obstipation und die darauf basierenden Darmerkrankungen, wie die Dys biose, persistierende Darmentzündungen, die Diverti kulose, der Morbus Crohn, die Darmpolyposis, die Co litis und das Carm-Ca, sowie koronare Herz- und Kreis lauferkrankungen inclusive Arteriosklerose und Herzin farkt, Krebs, Leukämie, Hypertonie, Allergien u. dgl.The enzymatic metabolic product according to the invention brings about the end supply to the cells by fermented biocatalysts in the form of an active ingredient complex of enzymes, amino acids, microfine dispersed medicinal plants, minerals and vitamins. Betazyans from the colored bodies of the beetroot and other red fruits support the O 2 utilization of the cells. The metabolic product is therefore a dietary product that produces an adequate, growth-optimal milieu of the human colon, i.e. a milieu below pH 6.0, with the simultaneous substitution of viable mixed cultures consisting of apathogenic intestinal lactobacilli and bifid strains. The application of this dietary product according to the invention brings about a therapy which includes the reanimation of the acid-forming intestinal flora or the resettlement of these floras and which is parallel to the therapy of the metabolically dependent skin disease, that is to say one of the numerous known civilization diseases, such as constipation and the bowel diseases based thereon, such as dysbiosis, persistent bowel inflammation, diverticulosis, Crohn's disease, intestinal polyposis, colitis and Carm-Ca, as well as coronary heart and circulatory diseases including arteriosclerosis and cardiac infarct, cancer, leukemia, hypertension, allergies and the like. the like
Das Verfahren zur Herstellung des erfindungsgemäßen en zymatischen Stoffwechselprodukts bedient sich der mikro feinen Zerkleinerung bzw. Zerlegung der Bestandteile der vegetabilen Masse durch einen oder mehrere bekannte Des integratoren, die auf das vegetabile Massengemisch mecha nische Schläge ausüben, und zwar gemäß einer vorteilhaf ten Verfahrensvariante bei gleichzeitiger Einwirkung eines statischen und/oder dynamischen Magnetfeldes oder eines elektrischen Spannungsfeldes auf die vegetabile Masse.The process for producing the en The micro uses the zymatic metabolic product fine crushing or disassembly of the components of the vegetable mass by one or more known des integrators based on the vegetal mass mixture mecha niche blows, according to an advantageous ten process variant with simultaneous action a static and / or dynamic magnetic field or of an electrical voltage field on the vegetable Dimensions.
Derartige Verfahren sind zur mechanischen Wasserbehand lung bekannt geworden (DE-OS 30 04 664), dienen jedoch dort zur Steuerung der Eigenschaften des Wassers durch Beeinflussung der molekularen Struktur durch Frequenz einwirkung mittels mechanischer Schläge, vorzugsweise von definierter Stärke, Zahl und Zeitfolge, um das Was ser zum Zwecke der Steigerung seiner Lösungsfähigkeit für ohne spezielle Zusätze schwer bis nicht lösbare oder emulgierbare Substanzen zu beeinflussen. Dabei ist da ran gedacht, die Eigenschaft des Wassers als Wasch- und Reinigungsmittel auch ohne oder mit wesentlich ver minderten Zugaben von Netzmitteln und konditionierenden Mitteln zu verbessern, insbesondere für Fette aufnahme fähiger zu machen.Such methods are for mechanical water treatment lung become known (DE-OS 30 04 664), but serve there to control the properties of the water Influencing the molecular structure by frequency action by mechanical blows, preferably of defined strength, number, and timing, to the what for the purpose of increasing its solvency for difficult or impossible to solve without special additives to influence emulsifiable substances. There is ran the property of water as a washing and cleaning agents without or with ver reduced additions of wetting agents and conditioning Improve funds, especially for fat intake to make more capable.
Das erfindungsgemäße Verfahren verfolgt eine andere Richtung, indem die Schlagwirkung des oder der Desinte gratoren eine mikrofeine Zerkleinerung und damit einen entsprechenden Aufschluß der Substanzen bewirken soll, aus denen die vegetabile Masse zusammengesetzt ist, um die Wirksamkeit dieser Substanzen zu erhöhen und ihre gegenseitige Reagenz zu verstärken und dadurch mittels dieser bioverfügbaren, reparativen Mechanismen Zellen, Regel- und Immunsysteme sowie die Selbstheilungskräfte, über die durch die hochkonzentrierte L-(+) -Milchsäure gaben physiologische Kompetenz des Dickdarmmilieus zu vitalisieren und zu stimulieren. The method according to the invention pursues a different one Direction by the impact of the disinte grators a microfine shredding and thus one should bring about appropriate digestion of the substances, of which the vegetable mass is composed in order to to increase the effectiveness of these substances and their reinforce mutual reagent and thereby by means of of these bioavailable, reparative mechanisms cells, Regulatory and immune systems as well as self-healing powers, through the by the highly concentrated L - (+) -lactic acid admitted physiological competence of the colon environment vitalize and stimulate.
Untersuchungen an Zerkleinerungsvorgängen haben gezeigt, daß die aufgewandte Energie bei bestimmten hochenergeti schen Verfahren größer ist als die Summe aus Zerkleine rungsarbeit und freigesetzter Wärme. Die Differenz ent spricht der Aktivierungsenergie. Sie ist im Mahlgut ge speichert und kann für verschiedene chemische und physi kochemische Folgereaktionen als Auslöser oder Reaktions verbesserung nutzbar gemacht werden, indem sie den Schwellenwert der betreffenden Reaktionen herabsetzt bzw. diese beschleunigt.Studies on shredding processes have shown that the energy expended at certain high energies process is greater than the sum of shredded materials work and released heat. The difference ent speaks of the activation energy. It is in the regrind stores and can be used for various chemical and physi subsequent chemical reactions as triggers or reactions improvement can be harnessed by using the Lowers the threshold of the relevant reactions or this accelerates.
Die vegetabile Masse aus Heilpflanzen, rote Bete, Früchten u. dgl., die durch Desintegration mikrofein zerkleinert und dispergiert wird, dient Mikroorganismen als Nährsubstrat, das die Zahl der Mikroben etwa alle 30 Minuten verdoppelt, wodurch in etwa auch die doppel te Menge an enzymatischen Stoffwechselprodukten erzeugt wird. Dies wiederum wirkt sich im Sinne einer Steigerung der Konzentration der Gesamt-Milchsäure auf ca. 5% aus.The vegetable mass of medicinal plants, beetroot, Fruits u. Like. That microfine by disintegration is crushed and dispersed, serves microorganisms as a nutrient substrate that the number of microbes about all Doubled 30 minutes, which roughly doubles te amount of enzymatic metabolites becomes. This in turn works in the sense of an increase the concentration of total lactic acid to about 5%.
So haben Versuchsergebnisse mit der Desintegrations- Technologie gezeigt, daß bei mechanisch aktivierten Nährkomponenten wie Glukose, Fruktose, Lactose, Saccha rose, Iryptophan u.ä., noch bei Konzentrationen der Biomasse von 0,002, 0,1, 0,5-1% gegenüber nicht akti vierten Nährkomponenten, die Biomasse alle 30 Minuten eine Verdoppelung erfährt.So test results with the disintegration Technology showed that when mechanically activated Nutritional components such as glucose, fructose, lactose, saccha rose, iryptophane and the like, still at concentrations of Biomass of 0.002, 0.1, 0.5-1% compared to non-active fourth nutrient components, the biomass every 30 minutes is doubled.
Als Indikationsobjekte erwiesen sich am günstigsten Mikroorganismen.The cheapest objects proved to be Microorganisms.
Folgende Stämme kamen u. a. zum Einsatz:
Staphylococcus citrus, Staphylococcus aureus, Strepto
coccus faecalis, Escherichia coli, L. acidophilus, Bak
terium bifidum, Hefe, Saccharomyces champagner u. a.
The following strains were used:
Staphylococcus citrus, Staphylococcus aureus, Strepto coccus faecalis, Escherichia coli, L. acidophilus, Bacterium bifidum, yeast, Saccharomyces champagne etc.
Beim Dispergieren der Nährkomponenten wurden relative Geschwindigkeiten bis 270 m/sec. gefahren.When dispersing the nutrient components were relative Speeds up to 270 m / sec. hazards.
Die Inkubationszeit betrug zwischen 24 und 48 Stunden bei Temperaturen von 37°C und 42°C.The incubation period was between 24 and 48 hours at temperatures of 37 ° C and 42 ° C.
Die Anzahl der Mikroben wurde u. a. auf Agarmedium durch Zählung der Kolonien festgestellt. Die Hefe- Mikroben wurden mittels der Gorjeav-Kammer gezählt.The number of microbes has been a. on agar medium determined by counting the colonies. Yeast- Microbes were counted using the Gorjeav chamber.
Somit wird erfindungsgemäß ein enzymatisches Stoffwech selprodukt aus darmresidenten Lacto- und Bifido-Bakte rien zur Gewinnung hochkonzentrierter L-(+)-Milchsäure zur Rückführung eines entgleisten Dickdarm-ph-Wertes in den Normbereich und Fermentation einer vegetabilen Masse zur Endversorgung der Zellen und deren Sauer stoff-Utilisation entwickelt, das sicherstellt, daß die Stoffwechselaktivitäten Ballensäure dekonjungieren der Chlosiridienkeime und ammoniakgasbildender Fäulnis floren das stoffwechseloptimale pH-Milieu entzogen wird, Entgiftungs-, Resorptions- und Stoffwechselfunktionen des Darms wieder in einem ausreichenden Maße erfüllt werden und die immunologischen Abläufe sowie die Selbst heilungskräfte aktiviert, so daß Obstipationen, colon irritabile, Völlegefühl, Gasbildung, Flatulenz und Mü digkeit sowie die durch diese Symptome erfolgende Aus lösung stoffwechselabhängiger Zivilisationskrankheiten mit ihren gefürchteten Komplikationen vermieden werden.Thus, according to the invention, an enzymatic metabolism Sel product from intestinal resident lacto and bifido bacteria for the production of highly concentrated L - (+) - lactic acid to return a derailed colon pH in the normal range and fermentation of a vegetable Mass for the final supply of the cells and their acid fabric utilization, which ensures that deconjugate the metabolic activities of bale acid Chlosiridien germs and ammonia gas-forming putrefaction the metabolically optimal pH environment is removed, Detoxification, absorption and metabolism functions of the intestine is satisfied to a sufficient extent and the immunological processes as well as the self healing powers activated so that constipations, colon irritable, feeling of fullness, gas formation, flatulence and tiredness severity as well as the end caused by these symptoms solution of metabolism-dependent diseases of civilization with their dreaded complications can be avoided.
Claims (3)
Mineraltiefbrunnen, Süßmolke-Konzentrat, Blüten pollen, Wildblütenhonig, Waldhonig, Sauerkraut, Brennessel, Löwenzahn und Wurzeln/Blätter/Blüten des schmalblättrigen Sonnenhuts, rote Bete, Heidelbeeren, Cassis und Karotten,
daß die Zutaten bestehen aus
Kalium, Calcium, Calcium Orthophosphat, Eisen, Vitamin dl-E-acetat, B1, B2, B6, Niacin und Ascorbinsäure, und
daß der Anteil der Vitamine etwa dem halben Deck ungsbedarf pro Tag, die Gesamtmilchsäure ca. 5%/100 ml und der pH-Wert 2,9-3,4 betragen.1. Enzymatic metabolic product from intestinal lacto and bifido bacteria for the production of highly concentrated L - (+) - lactic acid and fermentation of a vegetable mass for the final supply of the cells and their oxygen utilization, consisting of the vegetable mass, ingredients and vitamins, characterized that the vegetal mass composed of at least some of the following Vegetabil- and vital substances:
Mineral deep wells, sweet whey concentrate, pollen, wildflower honey, forest honey, sauerkraut, nettle, dandelion and roots / leaves / flowers of the narrow-leaved coneflower, beetroot, blueberries, cassis and carrots,
that the ingredients consist of
Potassium, calcium, calcium orthophosphate, iron, vitamin dl-E-acetate, B1, B2, B6, niacin and ascorbic acid, and
that the proportion of vitamins is about half the coverage requirement per day, the total lactic acid is about 5% / 100 ml and the pH is 2.9-3.4.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4032730A DE4032730A1 (en) | 1989-10-16 | 1990-10-15 | Enzymatic metabolic material for treating gastrointestinal disorders - produced from intestinal lacto- and bifido-bacteria, which are used to ferment a vegetable mass |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3934493 | 1989-10-16 | ||
DE4032730A DE4032730A1 (en) | 1989-10-16 | 1990-10-15 | Enzymatic metabolic material for treating gastrointestinal disorders - produced from intestinal lacto- and bifido-bacteria, which are used to ferment a vegetable mass |
Publications (1)
Publication Number | Publication Date |
---|---|
DE4032730A1 true DE4032730A1 (en) | 1991-04-18 |
Family
ID=25886151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE4032730A Withdrawn DE4032730A1 (en) | 1989-10-16 | 1990-10-15 | Enzymatic metabolic material for treating gastrointestinal disorders - produced from intestinal lacto- and bifido-bacteria, which are used to ferment a vegetable mass |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE4032730A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4132296C1 (en) * | 1991-09-27 | 1992-12-17 | Karl Heinz 8081 Schoengeising De Hoelzel | Enzymic metabolic prod. prepn. for intestinal disorders etc. - obtd. from pathogenic lacto- and bifido- bacteria from the gut |
EP2292105A1 (en) * | 2009-09-08 | 2011-03-09 | Hölzel, Evelyn | Dietetic product |
-
1990
- 1990-10-15 DE DE4032730A patent/DE4032730A1/en not_active Withdrawn
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4132296C1 (en) * | 1991-09-27 | 1992-12-17 | Karl Heinz 8081 Schoengeising De Hoelzel | Enzymic metabolic prod. prepn. for intestinal disorders etc. - obtd. from pathogenic lacto- and bifido- bacteria from the gut |
EP2292105A1 (en) * | 2009-09-08 | 2011-03-09 | Hölzel, Evelyn | Dietetic product |
DE102009040571A1 (en) * | 2009-09-08 | 2011-03-24 | Hölzel, Evelyn | dietetic |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69838988T2 (en) | METHOD AND COMPOSITIONS USING RED RICE FERMENTATION PRODUCTS | |
DE69936740T2 (en) | Oligosaccharide and probiotics containing preparation | |
AT407008B (en) | FORMULATIONS WITH PROBIOTALLY EFFECTIVE MICROORGANISMS | |
EP1952703B1 (en) | Product including living probiotic micro organisms | |
DE102006062250A1 (en) | Use of a composition of minerals and / or vitamins and optionally acetogenic and / or butyrogenic bacteria for oral or rectal administration for the treatment and prevention of abdominal discomfort | |
CH638660A5 (en) | METHOD FOR THE PRODUCTION OF FOODS AND BEVERAGES CONTAINING BIFIDOBACTERIES. | |
CH642517A5 (en) | METHOD FOR THE PRODUCTION OF FOODS AND BEVERAGES CONTAINING BIFIDOBACTERIES. | |
CN111631401A (en) | Traditional Chinese medicine enzyme and preparation method thereof | |
DE4132296C1 (en) | Enzymic metabolic prod. prepn. for intestinal disorders etc. - obtd. from pathogenic lacto- and bifido- bacteria from the gut | |
EP2560506A1 (en) | Process for producing a fermented natural product | |
DE4032730A1 (en) | Enzymatic metabolic material for treating gastrointestinal disorders - produced from intestinal lacto- and bifido-bacteria, which are used to ferment a vegetable mass | |
DE10008279A1 (en) | Synergistic medicinal or health-promoting food additive composition, comprising lactose, inulin and/or oligofructose, calcium salt and Bifidus bacteria, having e.g. immunostimulant and digestion improving action | |
EP2132994A1 (en) | Fermentation of solutions containing pomegranate juice with sacchatomyces boulardii and lactobacilli, resulting fermented products and application thereof | |
EP2292105B1 (en) | Dietetic product | |
EP1565197B1 (en) | Use of papaya puree for the treatment of digestive troubles | |
Hekmat et al. | Microbial properties of probiotic fermented milk supplemented with ginseng extracts | |
EP0482530B1 (en) | Composition for the regulation of intestinal flora | |
CN114190548A (en) | Microecological extract with arteriosclerosis intervention function and preparation method thereof | |
KR102217456B1 (en) | Fermenting method for honey using microorganism, fermented honey manufactured by the same and products using thereof | |
Al-Ogaidi et al. | The study of some chemical properties of Plantago ovata seeds and its utilization as synbiotics in fermented milk | |
EP0777489A1 (en) | Low molecular yeast active substance extract and process for preparing the same | |
EP0069995B1 (en) | Process for preparing a mixture of bee pollen having an improved resorption capacity, and a hyposensibilizing mixture of bee pollen | |
CN108159152A (en) | Pure acyl anticancer compound enzyme formula and production process thereof | |
AT412050B (en) | Fermented milk product useful as a food for people with a lactase deficiency comprises Saccharomyces cerevisiae boulardii and a prebiotic carbohydrate | |
WO2024026740A1 (en) | Fermentation composition with nmn anti-aging effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
8130 | Withdrawal |